Baek R, Coughlan K, Jiang L, Liang M, Ci L, Singh H
Nat Commun. 2024; 15(1):3804.
PMID: 38714648
PMC: 11076592.
DOI: 10.1038/s41467-024-47460-9.
Martinez M, Harding C, Schwank G, Thony B
J Inherit Metab Dis. 2023; 47(1):80-92.
PMID: 37401651
PMC: 10764640.
DOI: 10.1002/jimd.12651.
Elhawary N, AlJahdali I, Abumansour I, Elhawary E, Gaboon N, Dandini M
Hum Genomics. 2022; 16(1):22.
PMID: 35854334
PMC: 9295449.
DOI: 10.1186/s40246-022-00398-9.
Winn S, Dudley S, Scherer T, Rimann N, Thony B, Boutros S
Mol Genet Metab. 2022; 136(1):46-64.
PMID: 35339387
PMC: 9106909.
DOI: 10.1016/j.ymgme.2022.03.008.
Zhou L, Su J, Long J, Tao R, Tang W, Qin F
Mol Ther Methods Clin Dev. 2022; 24:230-240.
PMID: 35141352
PMC: 8803597.
DOI: 10.1016/j.omtm.2022.01.001.
Phenylketonuria.
van Spronsen F, Blau N, Harding C, Burlina A, Longo N, Bosch A
Nat Rev Dis Primers. 2021; 7(1):36.
PMID: 34017006
PMC: 8591558.
DOI: 10.1038/s41572-021-00267-0.
Prospects for Cell-Directed Curative Therapy of Phenylketonuria (PKU).
Harding C
Mol Front J. 2020; 3(2):110-121.
PMID: 32524084
PMC: 7286632.
DOI: 10.1142/s2529732519400145.
Animal Model Contributions to Congenital Metabolic Disease.
Moro C, Hanna-Rose W
Adv Exp Med Biol. 2020; 1236:225-244.
PMID: 32304075
PMC: 8404832.
DOI: 10.1007/978-981-15-2389-2_9.
AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria.
Richards D, Winn S, Dudley S, Nygaard S, Mighell T, Grompe M
Mol Ther Methods Clin Dev. 2020; 17:234-245.
PMID: 31970201
PMC: 6962637.
DOI: 10.1016/j.omtm.2019.12.004.
Forward genetic approach for behavioral neuroscience using animal models.
Funato H
Proc Jpn Acad Ser B Phys Biol Sci. 2020; 96(1):10-31.
PMID: 31932526
PMC: 6974404.
DOI: 10.2183/pjab.96.002.
State-of-the-Art 2019 on Gene Therapy for Phenylketonuria.
Grisch-Chan H, Schwank G, Harding C, Thony B
Hum Gene Ther. 2019; 30(10):1274-1283.
PMID: 31364419
PMC: 6763965.
DOI: 10.1089/hum.2019.111.
Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice.
Winn S, Scherer T, Thony B, Ying M, Martinez A, Weber S
Mol Genet Metab. 2018; 123(1):6-20.
PMID: 29331172
PMC: 5786171.
DOI: 10.1016/j.ymgme.2017.10.009.
Early-onset behavioral and neurochemical deficits in the genetic mouse model of phenylketonuria.
Fiori E, Oddi D, Ventura R, Colamartino M, Valzania A, DAmato F
PLoS One. 2017; 12(8):e0183430.
PMID: 28850618
PMC: 5574541.
DOI: 10.1371/journal.pone.0183430.
Low-Dose Gene Therapy for Murine PKU Using Episomal Naked DNA Vectors Expressing PAH from Its Endogenous Liver Promoter.
Grisch-Chan H, Schlegel A, Scherer T, Allegri G, Heidelberger R, Tsikrika P
Mol Ther Nucleic Acids. 2017; 7:339-349.
PMID: 28624210
PMC: 5423318.
DOI: 10.1016/j.omtn.2017.04.013.
Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.
Gessler D, Gao G
Methods Mol Biol. 2015; 1382:429-65.
PMID: 26611604
PMC: 4961359.
DOI: 10.1007/978-1-4939-3271-9_30.
Glycomacropeptide is a prebiotic that reduces Desulfovibrio bacteria, increases cecal short-chain fatty acids, and is anti-inflammatory in mice.
Sawin E, De Wolfe T, Aktas B, Stroup B, Murali S, Steele J
Am J Physiol Gastrointest Liver Physiol. 2015; 309(7):G590-601.
PMID: 26251473
PMC: 4593820.
DOI: 10.1152/ajpgi.00211.2015.
Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice.
Sawin E, Murali S, Ney D
Mol Genet Metab. 2014; 111(4):452-61.
PMID: 24560888
PMC: 3995025.
DOI: 10.1016/j.ymgme.2014.01.015.
Pharmacologic inhibition of L-tyrosine degradation ameliorates cerebral dopamine deficiency in murine phenylketonuria (PKU).
Harding C, Winn S, Gibson K, Arning E, Bottiglieri T, Grompe M
J Inherit Metab Dis. 2014; 37(5):735-43.
PMID: 24487571
PMC: 4119869.
DOI: 10.1007/s10545-013-9675-2.
Behavioral and neurochemical characterization of new mouse model of hyperphenylalaninemia.
Pascucci T, Giacovazzo G, Andolina D, Accoto A, Fiori E, Ventura R
PLoS One. 2013; 8(12):e84697.
PMID: 24376837
PMC: 3869930.
DOI: 10.1371/journal.pone.0084697.
Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet.
Solverson P, Murali S, Litscher S, Blank R, Ney D
PLoS One. 2012; 7(9):e45165.
PMID: 23028819
PMC: 3445501.
DOI: 10.1371/journal.pone.0045165.